Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma
Nishio R, Shinke T, Otake H, Nakagawa M, Nagoshi R, Inoue T, Kozuki A, Hariki H, Osue T, Taniguchi Y, Iwasaki M, Hiranuma N, Konishi A, Kinutani H, Shite J, Hirata K
Atherosclerosis · 112 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2014-03-06 · Atherosclerosis · vol. 234 · número 1 · págs. 114–119
- Editorial
- Elsevier BV
- Citado
- 133 citas · más que el 98% de estudios similares · 8.4× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 31 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Coronary Interventions and Diagnostics · Lipoproteins and Cardiovascular Health
- Palabras clave
- eicosapentaenoic acid, statin therapy, rosuvastatin, thin-cap fibroatheroma, coronary artery disease, pentraxin 3, fibrous cap thickness, lipid arc, macrophage accumulation, arterial inflammation, dyslipidemia, percutaneous coronary intervention
- MeSH
- humans, eicosapentaenoic acid, hydroxymethylglutaryl-coa reductase inhibitors, tomography, optical coherence, drug therapy, combination, middle aged, female, male, coronary artery disease, plaque, atherosclerotic
16 autores
- Ryo Nishio🇯🇵Kobe University
- Toshiro Shinke🇯🇵Kobe University
- Hiromasa Otake🇯🇵Kobe University
- Masayuki Nakagawa🇯🇵Kobe University
- Ryoji Nagoshi🇯🇵Kobe University
- Takumi Inoue🇯🇵Kobe University
- Amane Kozuki🇯🇵Kobe University
- Hirotoshi Hariki🇯🇵Kobe University
- Tsuyoshi Osue🇯🇵Kobe University
- Yu Taniguchi🇯🇵Kobe University
- Masamichi Iwasaki🇯🇵Kobe University
- Noritoshi Hiranuma🇯🇵Kobe University
- Akihide Konishi🇯🇵Kobe University
- Hiroto Kinutani🇯🇵Kobe University
- Junya Shite🇯🇵Kobe University
- Ken‐ichi Hirata🇯🇵Kobe University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
The addition of highly purified eicosapentaenoic acid (EPA) to statin therapy prevents cardiovascular events. However, the impact of this treatment on vulnerable plaques remains unclear. The aim of this study was to assess the impact of adding EPA to a standard statin therapy on vulnerable plaques by serial optical coherence tomography (OCT).
Methods
Forty-nine non-culprit thin-cap fibroatheroma (TCFA) lesions in 30 patients with untreated dyslipidemia were included. Patients were randomly assigned to EPA (1800 mg/day) + statin (23 TCFA, 15 patients) or statin only (26 TCFA, 15 patients) treatment. The statin (rosuvastatin) dose was adjusted to achieve a target low-density lipoprotein (LDL) level of <70 mg/dL. Post-percutaneous intervention and 9-month follow-up OCT were performed to evaluate morphological changes of TCFAs. The EPA/arachidonic acid (EPA/AA) ratio and pentraxin-3 (PTX3) levels were also evaluated.
Results
Despite similar follow-up LDL levels, the EPA + statin group had higher EPA/AA ratios and lower PTX3 levels than the statin group. OCT analysis showed that the EPA + statin group had a greater increase in fibrous-cap thickness, with a greater decrease in lipid arc and lipid length. Macrophage accumulation was less frequently detected in the EPA + statin group than in the statin group at follow-up. When the patients were categorized according to their follow-up PTX3 tertiles, fibrous-cap thickness showed significant increase, and the incidence of macrophages accumulation decreased with lower PTX3 levels.
Conclusion
The concomitant use of EPA and rosuvastatin may stabilize vulnerable plaques better than the statin alone, possibly by suppressing arterial inflammation.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.